Safety and clinical activity of oleclumab (O) ± durvalumab (D) plus chemotherapy (CT) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): A phase 1b/2 randomized study

被引：0

作者：

Coveler, Andrew L.

Reilley, Matthew

Zalupski, Mark

Macarulla, Teresa

Fountzilas, Christos

Castanon Alvarez, Eduardo

Nagrial, Adnan

Volodymyrivna Uboha, Nataliya

Frentzas, Sophia

Overman, Michael J.

Noonan, Anne M.

Messersmith, Wells A.

Pavlakis, Nick

Mettu, Niharika B.

Smith, Paul

Murtomaki, Elina

Bragulat, Veronique

Cooper, Zachary A.

Kumar, Rakesh

Spigel, David

机构：

[1] Fred Hutchinson Canc Ctr, Seattle, WA USA

[2] Univ Virginia, Ctr Comprehens Canc, Charlottesville, VA USA

[3] Univ Michigan Hlth Syst, Ann Arbor, MI USA

[4] Hosp Univ Vall DHebron, Barcelona, Spain

[5] Roswell Pk Canc Inst, Buffalo, NY USA

[6] Clin Univ Navarra, Madrid, Spain

[7] Blacktown Hosp, Sydney, NSW, Australia

[8] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA

[9] Monash Hlth Monash Med Ctr, Clayton, Vic, Australia

[10] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[11] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH USA

[12] Univ Colorado, Denver, CO USA

[13] Royal North Shore Hosp, Northern Sydney Canc Ctr, Sydney, NSW, Australia

[14] Duke Univ, Med Ctr, Durham, NC USA

[15] AstraZeneca, Cambridge, England

[16] AstraZeneca, Gaithersburg, MD USA

[17] Sarah Cannon Res Inst, Nashville, TN USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：1

共 50 条

[21] Safety and preliminary efficacy of ivaltinostat, an HDAC inhibitor, plus capecitabine in patients with pretreated metastatic pancreatic adenocarcinoma (mPDAC): Results of a phase Ib study.
Fountzilas, Christos
Ko, Andrew H.
Borazanci, Erkut Hasan
D'Olimpio, James Thomas
Hecht, Joel R.
Tang, Shou-Ching
Shields, Anthony F.
Salkeni, Mohamad Adham
Michelson, Glenn C.
Liganor, Lorna
Cho, Gene
Cho, Sangsook Ahn
Walker, Evan Justin
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL)
[22] A phase 1b/2, dose-escalation, randomized, multicenter study of maintenance (maint) ivaltinostat (ival) plus capecitabine (cap) or capecitabine monotherapy in patients (pts) with metastatic pancreatic adenocarcinoma (PDAC) whose disease has not progressed on first-line FOLFIRINOX chemotherapy (CT)
Walker, Evan Justin
Borazanci, Erkut Hasan
Botrus, Gehan
Fountzilas, Christos
Hecht, J. Randolph
Kasi, Anup
Mettu, Niharika B.
Pant, Shubham
Michelson, Glenn
Cho, Gene
Cho, Sangsook Ahn
Liganor, Lorna
Ko, Andrew H.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[23] Phase 1b/2 trial of pepinemab plus avelumab as second line combination immunotherapy for patients with metastatic pancreatic adenocarcinoma.
Ruffolo, Luis I.
Fisher, Terrence Lee
Evans, Elizabeth E.
Mallow, Crystal L.
Boise, Megan
Foster, Amber
Leonard, John E.
Belt, Brian A.
Yeh, Jen Jen
Zauderer, Maurice
Linehan, David
Mulkerin, Daniel
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[24] Napabucasin plus nab-paclitaxel with gemcitabine in patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC): Results from the phase III CanStem111P study
Bekaii-Saab, T.
Okusaka, T.
Goldstein, D.
Oh, D-Y.
Ueno, M.
Ioka, T.
Fang, W.
Anderson, E. C.
Noel, M. S.
Reni, M.
Choi, H. J.
Goldberg, J.
Oh, S. C.
Li, C-P.
Tabernero, J.
Li, J.
Foos, E.
Oh, C.
Van Cutsem, E.
ANNALS OF ONCOLOGY, 2021, 32 : S1084 - S1085
[25] A multi-cohort phase 1 study of ramucirumab plus durvalumab: Preliminary safety and clinical activity in patients with locally advanced and unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
Talia, Golan
Lin Chia-Chi
Fu Siqing
Heather, Wasserstrom
Mi Gu
Naomi, Laing
Maria, Karasarides
Yung-Jue, Bang
ANNALS OF ONCOLOGY, 2017, 28
[26] A randomized, multi-center, phase 2 study of ivaltinostat (Ival) plus capecitabine (Cape) versus capecitabine alone in the maintenance setting in patients with metastatic pancreatic adenocarcinoma (mPDAC)
Fountzilas, Christos
Ko, Andrew H.
Borazanci, Erkut Hasan
D'Olimpio, James Thomas
Hecht, J. Randolph
Tang, Shou-Ching
Shields, Anthony F.
Salkeni, Mohamad Adham
Michelson, Glenn
Cho, Gene
Liganor, Lorna
Cho, Sangsook Ahn
Walker, Evan Justin
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[27] Safety and clinical efficacy of IOA-289, a novel autotaxin inhibitor, plus gemcitabine and nab-paclitaxel (GnP) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC)
Melisi, Davide
Quinzii, Alberto
Valente, Monica
Di Giacomo, Anna Maria
Amato, Giovanni
Simonetti, Elena
Zecchetto, Camilla
Casallino, Simona
Leta, Luigi
Messineo, Luisa
Mendo, Lucia
Hammett, Tracey
Deken, Marcel
Di Conza, Giusy
Kaur, Paramjit
Lahn, Michael M. F.
Maio, Michele
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[28] A Phase 1B/2 trial of second line immunotherapy with pepinemab and avelumab for patients with metastatic pancreatic adenocarcinoma
Ruffolo, Luis I.
Byrne, Matthew
Hilty, Bailey
Belt, Brian A.
Dave, Yatee
Burchard, Paul
Fisher, Terrence
Evans, Elizabeth E.
Mallow, Crystal
Boise, Megan
Carpizo, Darren
Yeh, Jen Jen
Linehan, David C.
Mulkerin, Daniel
CANCER RESEARCH, 2024, 84 (17)
[29] RAMP 205: A phase 1b/2a study of gemcitabine, nab-paclitaxel, avutometinib, and defactinib in untreated metastatic pancreatic ductal adenocarcinoma
Lim, Kian-Haut
Hidalgo, Manuel
O'Hara, Mark H.
Spencer, Kristen R.
Garrido-Laguna, Ignacio
DeNardo, David G.
Bhambhani, Vijeta
Patrick, Gloria
Cheng, Yaofeng
Coma, Silvia
Pachter, Jonathan A.
Denis, Louis J.
CANCER RESEARCH, 2024, 84 (02)
[30] Randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine (PAG) vs AG in patients (Pts) with untreated, metastatic pancreatic ductal adenocarcinoma (mPDA).
Hingorani, Sunil R.
Bullock, Andrea J.
Seery, Tara Elisabeth
Zheng, Lei
Sigal, Darren
Ritch, Paul S.
Braiteh, Fadi S.
Zalupski, Mark
Bahary, Nathan
Harris, William Proctor
Pu, Jie
Aldrich, Carrie
Khelifa, Sihem
Wu, Xionghua W.
Baranda, Joaquina
Jiang, Ping
Hendifar, Andrew Eugene
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

← 1 2 3 4 5 →